Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

Novartis is expanding its prospects in cardiometabolic ... Anthos already has clinical trial results topping Xarelto. A Phase 2 test of abelacimab was stopped early in 2023 due to “overwhelming ...

Novartis has launched two trials pitching Cosentyx head-to-head with AbbVie’s Humira and one of its own biosimilars in a bid to increase its presence in a highly competitive market. Cosentyx ...

Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...

In this article, we are going to take a look at where Novartis AG (NYSE ... and distribute diagnostic tools and tests, takes the term "defensive" a step further than practically any other industry.

COLORECTAL CANCER SCREENING: New York City Health + Hospitals screened close to 60,000 people for colorectal cancer in 2024 ...

STAND found no benefit over placebo on VOC rates for both doses of Adakveo on test – 5 mg/kg and 7.5 mg/kg, given as a 30-minute infusion once a month – which Novartis said was "inconsistent ...

This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...